|
PF-7613 |
Intron A 3 millones UI polvo y solucion para uso parenteral |
2007-07-17 |
|
Sp (brinny) Company |
Irlanda
|
Bodega Farmacéutica S.A. |
Colon S.A. |
Agencias J.i. Cohen |
Lanquetin S.A. |
Merigal S.A. |
Refasa S.A. |
Union De Farmaceuticos S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29443 |
Intron-5 millones UI polvo para solucion inyectable |
2007-12-30 |
|
Sp (brinny) Company |
Irlanda
|
Bodega Farmacéutica S.A. |
Colon S.A. |
Agencias J.i. Cohen |
Lanquetin S.A. |
Refasa S.A. |
Union De Farmaceuticos S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59740 |
OXAL SPAL-L 100, 100 mg solución inyectable |
2026-07-29 |
|
SPAL Private Limited |
India
|
Bikasa |
Arael de Centro América |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59806 |
PALIT SPAL 100 mg (Paclitaxel unido a proteinas de albumina) Polvo liofilizado para suspensión inyectable |
2026-08-06 |
|
SPAL Private Limited |
India
|
Bikasa |
Arael de Centro América |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-60025 |
BORT SPAL 3.5, 3.5 mg Polvo para uso parenteral |
2026-09-16 |
|
SPAL Private Limited |
India
|
Bikasa |
Arael de Centro América |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-60226 |
CARBOPLATINO Spal 10 mg/ mL Solución inyectable |
2026-10-18 |
|
SPAL Private Limited |
India
|
Bikasa |
Arael de Centro América |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-60283 |
AZACT SPAL 100 mg Polvo para suspensión inyectable |
2026-10-27 |
|
SPAL Private Limited |
India
|
Arael de Centro América |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-47925 |
SLOVAR ® 3 g Gránulos para Solución Oral |
2017-10-30 |
|
MG Pharma |
Italia
|
Dalt Pharma |
Coidesa |
Dimefasa |
Amicelco |
Asta Médica Centroamericana |
Servicio De Comercio Internacional |
Altian Pharma |
Medesa |
Droguería Y Farmacia Lanquetin |
Vipro |
|
|
|
|
|
|
|
|
|
|
|
PF-34505 |
ANGIMED Pastillas (lozenges) |
2020-01-05 |
|
Medinova Ltd. |
Suiza
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PFD-35035 |
Man Factor Caplet |
2010-03-22 |
|
Splash Internacional, S. De R.L. De C.V. |
Mexico
|
Splash Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|